|
The Annual Drug Repositioning, Repurposing & Rescue Conference announces Bruce Bloom of Cures Within Reach and Aris Persidis of Biovista as conference chairs.
Online PR News – 04-June-2014 – The 3rd Annual Drug Repositioning, Repurposing and Rescue Conference announces Bruce Bloom of Cures Within Reach and Aris Persidis of Biovista as conference chairs. The event will be held on July 15 & 16, 2014 at the Sheraton Commander hotel in Boston, MA. The focus of the conference is on explorations into new therapeutics entities; crowd funding and collaborative drug discovery and development. Following is the conference agenda:
Why High Quality Phenotypic Screening is So Well Suited for Drug Repositioning – Andrew Reaume, Melior Discovery, Inc.
Social Investing to Support Rediscovery Research – Dr. Bruce Bloom, Cures Within Reach
The Challenges of Repositioning Drugs: 10 lessons From Black Bone Disease – Nicholas Sireau, AKU Society, Co-Founder, Findacure
The Drug Repurposing Patent Landscape: A Hotbed of Pharmaceutical Creativity – Hermann Mucke, Ph.D., H.M. Pharma Consultancy
Prioritizing and Integrating Existing Methods into Cost-effective and Efficient Pipelines for Drug Repositioning – Stephen Wong, The Methodist Hospital Research Institute, Weill Cornell Medical College at Texas Medical Center
Comparison of Different Development Paths, Challenges and Profiles of Three Re-positioned Drug Products – Neal M. Farber, NeuroHealing Pharmaceuticals, Inc.
The NCATS Pharmaceutical Collection: Overview, Screening Processes, and Examples of Use in Cancer and Infectious Diseases – Anton Simeonov, National Center for Advancing Translational Sciences, National Institutes of Health
Drug Repurposing In Pediatrics: A Clinician’s Perspective – Julie Blatt, University of North Carolina School of Medicine
Repositioning: Validating a Drug Target for a New Indication through Genetics, Expression, and Phenotypic Screening – Pankaj Agarwal, GlaxoSmithKline
Presentation by Mary E. Ogle, Teva Pharmaceuticals
Repurposing as a Viable, Risk-managed Business Model – Daniel Behr, Rediscovery Life Sciences
Integrating the Digital Universe of Information for Drug Discovery and Repurposing – Joel Dudley, Mount Sinai School of Medicine
Rethinking Design and Execution of Clinical Trials for Repositioned Drugs – Marc Foster, Transparency Life Sciences
Celgene Global Health: Focusing on Those Who Can Least Afford to Live by Re-focusing a Proprietary Chemical Library – Jerome B. Zeldis, Celgene Global Health
Next Generation Repositioning: Taking the Serendipity Out – Aris Persidis, Biovista, Inc.
Development of a Topical Anti-inflammatory Compound Using Smart Re-Profiling – Dr. Robert Scoffin, Cresset, Co-Founder, Re-Pharm
Repositioning of Drugs for Renal Cell Cancer Using Transcriptome Signatures – Towia Libermann, Beth Israel Deaconess Medical Center
Pushing the Boundaries of Science Together Through Open Innovation Partnerships – Craig D. Wegner, AstraZeneca Pharmaceuticals LP
Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
For more information on this informative and exciting event please visit: www.drugrepositioningconference.com
Hilary Simonson
Arrowhead Publishers
866.945.0263 x702
Hilary.simonson@arrowheadpublishers.com
|
